Synopsis: The government’s Rs. 10,000 crore Biopharma SHAKTI scheme aims to strengthen India’s biologics ecosystem through funding, infrastructure, and clinical research. Six pharmaceutical stocks including Biocon, Syngene International and others, could benefit from the country’s push towards biopharma innovation and self-reliance.
India’s biopharmaceutical industry is poised for significant growth as the government intensifies its focus on innovation-led healthcare. Through the Rs. 10,000 crore Biopharma SHAKTI scheme, the country aims to strengthen capabilities in biologics, biosimilars, advanced therapies, and contract research over the next five years.
The initiative also targets the creation of a network of 1,000 accredited clinical trial sites while increasing India’s share in the global biopharmaceutical market. As investments in research, manufacturing, and drug development accelerate, companies operating across biologics, biosimilars, and CRDMO services are expected to be key beneficiaries.
Overview and Objectives of the Scheme
The Government of India has announced the Biopharma SHAKTI (Sustainable Health and Advanced Knowledge Transformation Initiative) scheme, under the Ministry of Chemicals and Fertilizers’ Department of Pharmaceuticals.
With a substantial financial outlay of Rs. 10,000 crore over five years, the scheme aims to reinforce the domestic biopharmaceutical sector and significantly enhance India’s global competitiveness in biologics and biosimilars.
The primary goal is to establish a globally competitive domestic ecosystem that supports affordable healthcare within India while positioning the nation as a premier global hub for biopharma manufacturing and innovation.
Core Pillars and Focus Areas
The scheme targets the entire biopharmaceutical value chain from initial discovery to final packaging by focusing on seven critical components:
- Research & Funding: Establishing the Biopharma Discovery Grant Fund and the Discovery & Development Equity Fund to fuel early-stage innovation.
- Academic & Institutional Networks: Creating a biopharma-focused NIPER (National Institute of Pharmaceutical Education and Research) Network alongside a National Biopharma R&D Network.
- Infrastructure & Manufacturing: Launching incentives for fermentation-based bulk drugs and building blocks, setting up a manufacturing ecosystem for delivery devices and packaging, and driving the Biosimilars & Emerging Biologics Manufacturing Initiative.
- Clinical Research: Building the India Clinical Trial Sites Network to expand the nation’s medical research footprint.
Clinical Trial Expansion and Regulatory Overhaul
A major highlight of the Biopharma SHAKTI scheme is its focus on upgrading infrastructure and regulatory efficiency to meet global standards. It envisages the creation of a nationally accredited network of 1,000 clinical trial sites under the Indian Council of Medical Research (ICMR).
To ensure faster and globally credible drug approvals, the Central Drugs Standard Control Organisation (CDSCO) will be strengthened. This includes establishing a dedicated Scientific Review Cadre of reviewers and introducing specialist positions tailored for advanced medical fields, such as gene therapy.
Economic and Healthcare Impact
By fostering deep collaboration among academia, research institutions, and the manufacturing industry, the initiative aims to catalyze domestic innovation and self-reliance. Strengthening the local production ecosystem for biologics and biosimilars is expected to progressively reduce India’s import dependence on critical medical products.
Ultimately, these measures are designed to enhance India’s market share in the global biopharmaceutical arena while ensuring that advanced, life-saving treatments remain highly affordable for the domestic population.
Stocks that could benefit
Syngene International Ltd
Syngene International Ltd is one of India’s leading contract research, development, and manufacturing (CRDMO) companies. It provides integrated services spanning drug discovery, development, biologics, and commercial manufacturing to global pharmaceutical and biotechnology companies. With a market capitalisation of Rs. 16,728 cr, the shares of Syngene International Ltd closed at Rs. 414.40 per share, down from its previous close of Rs. 417.50 per share.
Biocon Ltd
Biocon Ltd is one of the leading biopharmaceutical companies engaged in the development and manufacturing of biologics, biosimilars, generic formulations, and active pharmaceutical ingredients (APIs). It has a strong global presence and is among India’s largest biosimilars manufacturers. With a market capitalisation of Rs. 71,465 cr, the shares of Biocon Ltd closed at Rs. 440.90 per share, up from its previous close of Rs. 436.25 per share.
Laurus Labs Ltd
Laurus Labs Ltd is a pharmaceutical company focused on APIs, formulations, contract development and manufacturing (CDMO), and biotechnology products. The company has been expanding its biologics and advanced manufacturing capabilities to cater to global pharmaceutical demand. With a market capitalisation of Rs. 86,059 cr, the shares of Laurus Labs Ltd closed at Rs. 1592.95 per share, up from its previous close of Rs. 1,559.20 per share.
Divis Laboratories Ltd
Divis Laboratories Ltd is one of India’s largest manufacturers of active pharmaceutical ingredients (APIs), intermediates, and custom synthesis products. The company serves leading global pharmaceutical firms and has a strong presence in contract manufacturing and high-value pharmaceutical ingredients. With a market capitalisation of Rs. 1,94,646 cr, the shares of Divis Laboratories Ltd closed at Rs. 7332.20 per share, up from its previous close of Rs. 7,321.95 per share.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is a diversified pharmaceutical company engaged in the manufacture and marketing of generic medicines, APIs, injectable products, and biosimilars. It exports its products to more than 150 countries and continues to strengthen its presence in biologics. With a market capitalisation of Rs. 90,386 cr, the shares of Aurobindo Pharma Ltd closed at Rs. 1570.90 per share, up from its previous close of Rs. 1,560.55 per share.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd is a global pharmaceutical company engaged in generic medicines, biosimilars, APIs, and proprietary products. The company has a growing biosimilars portfolio and operates across major international markets, including the US, Europe, and emerging economies. With a market capitalisation of Rs. 1,00,703 cr, the shares of Dr Reddys Laboratories Ltd closed at Rs. 1206.55 per share, down from its previous close of Rs. 1,223.30 per share.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
